Injectable veterinary compositions formed by the association of sulfoxides derivatives of benzimidazole or a salt, acid or basic with lactones macrocu00ecclicas indicated for the treatment of parasites inteRnos and external cattle, sheep, pigs and goats.

摘要

"Injectable veterinary compositions formed by the association of sulfoxides derivatives of benzimidazoles or a salt, acid or basic with lactones macrocu00ecclicas indicated for the treatment of parasites intErnos and external of bovine, ovine and caprine animals, suu00ecnos ".The present invention relates new injectable veterinary pharmaceutical compositions formed by the combination of compounds of the a type MV the sulfoxides derivatives of benzimidazoles (Figure 1) Co.M composed of a b MV suckles member is represented by: lvermectin, abamectinas avermectin, doramectin, moxidectin,Milbemycin derivatives of such compounds and composition; this injectable veterinary may be presented in the following forms: 1, an injectable solution in which both the active compoundS a A and B MV, are dissolved in a solvent (s) in the formulation.II - an injectable suspension in which one of the active ingredients compounds of the a type A or B MV is dissolved in a solvent (s) that make up the formulation and the other active principle compounds of the a Type A or B MV is in suspension coated or not. III - an injectable suspension in which both active compounds of the a A and B MV are in suspension.IV - an injectable solution tank whose preparation is to make at the time of application, by the addition of solution of one of the active ingredients compounds of the a a MV ,Solution this prepared previously or prepared at the time of its implementation on the solution of other active ingredient compounds of the a b MV in solvent (s) appropriate (s).V - an injectable emulsion tank whose preparation is to make at the time of your application.Formed by the addition of solution of one of the active ingredients compounds of the a type MV dissolved in a solvent or mixture of solvents on the solution of the appropriate other active ingredient compoundS a b MV dissolved in a solvent or mixture of solvents emuisu00e3o if appropriate; the way in which the solvent in the solution of compounds of type a are not miscible with MV.The solvent in the solution of compounds of type B.I saw an emulsion tank whose preparation is carried out at the time of your application; the solution of compounds of type a MV is prepared at the time by the addition of the solvent (s) on a salt (u00e1ciOf or alkaline) of a compound of the a MV type or addition of solutions of acids or alkalis on the compounds of the type powder or suspension in the solvent (s) appropriate (s); then this solution REC.But prepared is mixed with a solution of compounds of a b MV.The emulsion is formed by the solvent in the solution of compounds of type a MV are not miscible with the solvent of the solution of compounds of a b MV; and VII - an EMULsu00e3o injectable preparation tank which is made at the time of its implementation.Initially we have a mixture formed by the suspension of the a type compounds to MV in solvents immiscible with the solvent dissolving the compounds are a b MV.When the application is added to the mixture described above.A solution of an acid or a base dissolved in water, and is stirred to obtain a stable emulsion or microemulsion formed by solution of compounds of type a MV with the solution of the comp.The a ostos type B MV ; the structure of compounds of type a MV is the following: (Figure 1) where R ^ 1 ^ is a chain alkyl or phenyl alkyl and R ^ 2 ^ is an alkyl chain lengths.As well as their salts, acid or basic, used in several injectable formulations to increase the solubility of sulfoxides derivatives of a strains; as an example we have sulfu00f3xidThe of albendazole, where R ^ 1 ^ is propyl and R ^ 2 - methyl, oxfendazole where R ^ 1 ^ is phenyl, and R ^ 2 ^ methyl; and salts derived from these examples we have, the cioridrato of albendazole sulphoxide.The methane of albendazole sulphoxide, the sodium salt of albendazole sulphoxide, the potassium salt of albendazoi sulfoxide and etc; for the structure.And characterization of compounds of type a b MV can refer to the technical and commercial literature widely available: for avermectin, ivermectin and abamectin.Reference may be made, for example, to work a ivermectin and abamectin MV, 1989 by M. h. Fischer and H. mrozik, William C. Campbell ed. Springer Verlag or Albers schu00f7nberg et al.(1981) a avermectins structure deternlination MV. J. am. Chem. SOC. 103: 4216 - 4221; for doramectin can consult especially a veterinary parasitology MV Vol.49 n 0 1, July 1993: 5 - 15; for the milbemycin, we can refer to, among others, the Davies H. G. et al. 1986, a avermectins and milbemvcins MV ; NAT. Prod. Rep.3: 87 - 121, mrozik h et al., 1983, a synthesis of milbemycins from avermectins MV , a tetrahedron lett MV.24: 5333 - 5336, like us - - 4 134 973; the resulting solutions can be administered to cattle, sheep,Pigs and goats infected with parasites and internal or external in a single dose; the concentration of the active principles varies from 2.5% to 15% to the sulfoxide derivatives of benzimidazoles (compounds of the type A) and 0.4% to 1.5% of the macrocu00ecclicas lactones (compounds of type (b) in the final composition of the specialty of veterinary pharmaceuticals; pharmaceutical composition for use is also provided; the dose of active principlesFor body weight is the following: - for the sulfoxides derivatives of benzimidazoles (compounds of a type MV ) varies from 1.5 mg per kilogram of body weight 6,0 mg per kilogram of body weight.For the macrocu00ecclicas lactones (compounds of a b MV) varies from 0.1 mg per kilogram of body weight to 0.4 mg per kilogram of body weight.